Buy Advanced Enzyme Technologies Ltd For Target Rs.380 - ICICI Direct
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Logistical issues, RM inflation continue to weigh…
About the stock: Advanced Enzyme Technologies (AET) is a focused, research driven Indian enzymes company with a product basket of 400+ proprietary products developed from 68 indigenous enzymes and probiotics.
The business is divided into three segments - 1) human healthcare, 2) animal healthcare and 3) industrial processing business
It has seven manufacturing and six R&D facilities, which consist of three integrated fermentations, recovery & formulation facilities, one extraction and recovery facility and one satellite blending, mixing & formulation facility
Q3FY22 Results: Margin pressure due to logistics challenge and high raw material cost continues to weigh on numbers.
Revenues were up 3% YoY to | 133.6 crore
EBITDA was at | 49.1 crore, down 26.1% YoY with margins at 36.7%
Adjusted PAT was at | 27.5 crore (down 36.2% YoY)
What should investors do? AET’s share price has de-grown by ~0.9x over the past five years (from ~| 358 in February 2017 to ~| 319 levels in February 2022)
Below-par performance notwithstanding, we retain BUY as we expect normalcy to return by H2FY23. The momentum in core Enzymes businesses of Probiotics, bio-catalysis, animal nutrition, baking, etc, is likely to persist under normal circumstances
Target Price and Valuation: We value AET at | 380 i.e. 24x FY24E EPS of | 15.8
Key triggers for future price performance:
Easing of input cost inflation as well as logistical challenges
AET remains a marginal player in the global enzymes landscape that is estimated at ~US$10 billion and poised to grow as more applications across usage industries incorporate enzymatic technologies
It has got proven capabilities and stable financials, thanks to a mix of organic and inorganic growth strategy employed by management
Going ahead, AET plans to augment its R&D capability that bodes well in the long run in its quest to improve scalability & foraying into complex enzymes
Alternate Stock Idea: Apart from AET, in our healthcare coverage we like Laurus
Laurus is evolving as a strong vertically integrated player with strong order book visibility and incremental traction from custom synthesis
BUY with a target price of | 625
To Read Complete Report & Disclaimer Click Here
https://secure.icicidirect.com/Content/StaticData/Disclaimer.html
Views express by all participants are for information & academic purpose only. Kindly read disclaimer before referring below views. Click Here For Disclaimer
